62981 20210310171107.0 doi 10.2174/1381612822666161226151011 sideral 101084 ART-2017-101084 eng (orcid)0000-0003-0702-8260 Martín-Rapún, R. Targeted nanoparticles for the treatment of Alzheimer’s disease 2017 Access copy available to the general public Unrestricted Background: Alzheimer’s disease (AD) has a dramatic impact on society. The therapeutic targets are located in the central nervous system (CNS), which limits the efficacy of drugs systemically administered: the blood-brain barrier (BBB) selectively allows the permeation of just a few kinds of molecules from the systemic circulation to the CNS. On the other hand, local administration routes to CNS are highly invasive. Methods: In this article, we have reviewed therapeutic approaches against AD, which are based on nanoparticles targeted to the brain and to the pathological hallmarks of the disease. The existing literature has been classified according to the AD feature that is addressed. Results: Nanoparticles have been used for the targeted delivery of drugs aiming to reduce the AD symptoms or to reverse the course of the disease. For this task the multivalency of nanoparticles has allowed their functionalization with several kinds of targeting groups, to cross the BBB and to target the place of treatment. With this approach an increased drug bioavailability has been achieved in the CNS using intravenous administration in place of more invasive administration routes. Additionally, nanoparticles have also been used in the development of vaccines and therapeutic formulations for intranasal administration. Conclusion: Targeted nanoparticles have been proved useful to enhance the performance of therapies against AD in animal models. A better understanding of AD mechanisms will help the successful application of targeted nanoparticles for combined therapies. info:eu-repo/grantAgreement/ES/MINECO/RYC-2014-15512 info:eu-repo/grantAgreement/ES/MINECO/RYC-2013-12570 This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 657566-CONFINES info:eu-repo/grantAgreement/EC/H2020/657566/EU/Controlling Cell Fate through Smart Nanoheaters/CONFINES info:eu-repo/grantAgreement/ES/DGA/E93 info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 2.757 2017 PHARMACOLOGY & PHARMACY 114 / 261 = 0.437 2017 Q2 T2 0.883 2017 Pharmacology 2017 Q2 Drug Discovery 2017 Q2 info:eu-repo/semantics/review info:eu-repo/semantics/acceptedVersion (orcid)0000-0001-6995-4302 de Matteis, L. (orcid)0000-0002-1897-4028 Ambrosone, A. (orcid)0000-0002-7407-6177 García-Embid, S. (orcid)0000-0003-2366-3598 Gutiérrez, L. Universidad de Zaragoza (orcid)0000-0003-1081-8482 de la Fuente, J.M. Universidad de Zaragoza 2009 750 Universidad de Zaragoza Dpto. Química Analítica Área Química Analítica 2013 765 Universidad de Zaragoza Dpto. Química Orgánica Área Química Orgánica 23, 13 (2017), 1927-1952 Curr. pharm. des. Current pharmaceutical design 1381-6128 2957841 http://zaguan.unizar.es/record/62981/files/texto_completo.pdf Postprint 110063 http://zaguan.unizar.es/record/62981/files/texto_completo.jpg?subformat=icon icon Postprint oai:zaguan.unizar.es:62981 articulos driver 2021-03-10-17:00:50 ARTICLE